Guidelines for the automated evaluation of Elispot assays
Sylvia Janetzki(Yale University), Axel Hoos(GlaxoSmithKline (United States)), Hélène Schroeder(Centre Hospitalier Universitaire de Liège), Cedrik M. Britten(Johannes Gutenberg University Mainz), Marij J.P. Welters(Leiden University Medical Center), Leah Price(Cwm Taf University Health Board)
Cited by 88
Related Papers
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2015|1.3k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Triple-negative breast cancer: treatment challenges and solutions
|Breast Cancer Targets and Therapy|2016|382
A Clinical Development Paradigm for Cancer Vaccines and Related Biologics
|Journal of Immunotherapy|2006|271